Clinical trial
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
NCT00002947 · Yale University, Other · Terminated
Key facts
| NCT number | NCT00002947 |
|---|---|
| Title | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer |
| Official title | A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors |
| Lead sponsor | Yale University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome and 2 more |
| Intervention type | Radiation |
| Interventions | indium In 111 pentetreotide |
| Enrollment | 35 |
| Start date | Oct 1, 1996 |
| Primary completion | Aug 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | Mar 26, 2004 |
| Last update posted | Jul 2, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: